Intraocular pressure alterations following intravitreal triamcinolone acetonide

British Journal of Ophthalmology

Volumn 90, Issue 8, 2006, Pages 999-1003

  Rhee, Douglas J ^a,b   Peck, R E ^b   Belmont, J ^b   Martidis, A ^b   Liu, M ^b   Chang, J ^b   Fontanarosa, J ^b   Moster, M R ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; GASTROINTESTINAL AGENT; STEROID; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; RISK FACTOR; TREATMENT OUTCOME; UVEITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33746509667     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.090340     Document Type: Article

References (30)

1. Benhamou N, Massin P, Haochine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-9.
2. Conway MD, Canakis C, Livir-Rallatos C, et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
3. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZJ Ophthalmol 1998;26:277-81.
4. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:067-73.
5. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-22.
6. Jonas JB, Kreissig I, Degenrig RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graetes Arch Clin Exp Ophthalmol 2002;240:782-3.
7. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
8. Jonas JB, Degenring RF, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-60.
9. Jonas JB, Hayler JK, Sofker A, et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001;10:284-7.
10. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-16.
11. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
12. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg lasers Imaging 2003;43:386-90.
13. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthal 1999;27:431-432.
14. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
15. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-40.
16. Park CH, Jaffe FJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-25.
17. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide fro diabetic diffuse macular edema: preliminary results of a prospective clinical trial. Ophthalmology 2004;111:224-5.
18. Kaushik S, Gupta V, Gupta A, et al. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004;137:758-60.
19. Jonas JB, Degenrigh RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-8.
20. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone and intraocular pressure. Am J Ophthalmol 2004;138:740-3.
21. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-7.
22. Armaly MF. Dexamethasone ocular hypertension in the clinically normal eye. II. The untreated eye, outflow facility, and concentration. Arch Ophthalmol 1966;75:776-82.
23. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
24. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-7.
25. Jonas JB, Degenring RF, Kreissig I, et al. Safety of intravitreal high-dose reinjections or triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-5.
26. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;26:198-205.
27. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 1965;4:187-97.
28. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6.
29. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-2.
30. Jonas JB, Kreissig I, Degenring RF. Secondary chronic open angle glaucoma after triamcinolone acetonide. Arch Ophthalmol 2003;121:729-30.